Pre-S Deletions are Predominant Quasispecies in HIV/HBV Infection: Quasispecies Perspective.
Pre-S region
deletion
hepatitis B virus
human immunodeficiency virus
quasispecies
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
03
2020
accepted:
16
05
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
2
7
2020
Statut:
epublish
Résumé
Combined HIV infection can accelerate HBV-induced liver disease. It is known that HBV Pre-S deletion is closely related to HBV-associated terminal liver disease in HBV mono-infection. Currently, data on HBV Pre-S quasispecies feature deletion in HIV/HBV co-infected patients are lacking. The characteristics and blood samples of patients with chronic HBV infection were collected and classified into an HIV/HBV co-infection group and an HBV mono-infection group according to HIV antibody results before treatment. HBV DNA in serum was extracted. The HBV Pre-S region was amplified by nested-PCR and was further T-A cloned. Using the standard sequence of the matched genotype HBV as a reference, BioEdit 7.0 software was employed for sequence alignment. HBV Pre-S regions were successfully amplified from 147 patients, including 71 cases in the HIV/HBV co-infected group and 76 cases in the HBV mono-infected group. The proportion of the HIV/HBV co-infected group with Pre-S quasispecies deletion was lower than that of the HBV mono-infected group. By analyzing the frequency of Pre-S quasispecies in the two groups, the frequency of Pre-S quasispecies in HIV/HBV co-infected patients with Pre-S quasispecies was higher than HBV mono-infected patients. The frequency of Pre-S quasispecies deletion of the S protein promoter region in the HIV/HBV co-infected group was significantly higher than that in the HBV mono-infected group. High-frequency Pre-S quasispecies deletions are predominant in HIV/HBV co-infected patients; however, low-frequency Pre-S deletions are predominant in HBV mono-infected patients, providing a reference for the pathogenesis of the accelerated progression of liver disease in HIV/HBV co-infection.
Sections du résumé
BACKGROUND
BACKGROUND
Combined HIV infection can accelerate HBV-induced liver disease. It is known that HBV Pre-S deletion is closely related to HBV-associated terminal liver disease in HBV mono-infection. Currently, data on HBV Pre-S quasispecies feature deletion in HIV/HBV co-infected patients are lacking.
METHODS
METHODS
The characteristics and blood samples of patients with chronic HBV infection were collected and classified into an HIV/HBV co-infection group and an HBV mono-infection group according to HIV antibody results before treatment. HBV DNA in serum was extracted. The HBV Pre-S region was amplified by nested-PCR and was further T-A cloned. Using the standard sequence of the matched genotype HBV as a reference, BioEdit 7.0 software was employed for sequence alignment.
RESULTS
RESULTS
HBV Pre-S regions were successfully amplified from 147 patients, including 71 cases in the HIV/HBV co-infected group and 76 cases in the HBV mono-infected group. The proportion of the HIV/HBV co-infected group with Pre-S quasispecies deletion was lower than that of the HBV mono-infected group. By analyzing the frequency of Pre-S quasispecies in the two groups, the frequency of Pre-S quasispecies in HIV/HBV co-infected patients with Pre-S quasispecies was higher than HBV mono-infected patients. The frequency of Pre-S quasispecies deletion of the S protein promoter region in the HIV/HBV co-infected group was significantly higher than that in the HBV mono-infected group.
CONCLUSION
CONCLUSIONS
High-frequency Pre-S quasispecies deletions are predominant in HIV/HBV co-infected patients; however, low-frequency Pre-S deletions are predominant in HBV mono-infected patients, providing a reference for the pathogenesis of the accelerated progression of liver disease in HIV/HBV co-infection.
Identifiants
pubmed: 32606815
doi: 10.2147/IDR.S255473
pii: 255473
pmc: PMC7294102
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1643-1649Informations de copyright
© 2020 Nie et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest.
Références
J Virol. 2011 Jan;85(1):123-32
pubmed: 20962085
Cancer Sci. 2006 Aug;97(8):683-8
pubmed: 16863502
J Clin Virol. 2009 Dec;46(4):354-9
pubmed: 19800842
Carcinogenesis. 2004 Oct;25(10):2023-32
pubmed: 15180947
Gut. 2011 Sep;60(9):1269-77
pubmed: 21292683
N Engl J Med. 2012 May 10;366(19):1749-52
pubmed: 22571198
J Pept Sci. 2008 Mar;14(3):307-12
pubmed: 17918766
J Infect Dis. 2011 Mar 1;203(5):646-54
pubmed: 21227916
J Virol. 2010 Apr;84(8):3879-88
pubmed: 20130049
Virology. 2010 Sep 30;405(2):539-47
pubmed: 20655563
Hepatology. 2008 Jul;48(1):88-98
pubmed: 18537180
Lancet Infect Dis. 2014 Nov;14(11):1065-1072
pubmed: 25303841
Virus Res. 2017 Jan 2;227:88-95
pubmed: 27720823
AIDS. 2007 Aug 20;21(13):1701-10
pubmed: 17690567
J Med Virol. 2010 Nov;82(11):1843-9
pubmed: 20872710
J Pathol. 2017 Mar;241(4):463-474
pubmed: 27868197
Clin Microbiol Infect. 2015 Jul;21(7):710.e11-20
pubmed: 25882358
Lancet. 2002 Dec 14;360(9349):1921-6
pubmed: 12493258
Lancet Oncol. 2016 Nov;17(11):e484
pubmed: 27773486
Gastroenterology. 2006 Apr;130(4):1153-68
pubmed: 16618410
World J Gastroenterol. 2018 Aug 21;24(31):3488-3499
pubmed: 30131655
Antivir Ther. 2008;13(2):161-75
pubmed: 18505168
World J Gastroenterol. 2014 May 14;20(18):5435-41
pubmed: 24833874